Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (29)

« Back to Publications

Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.

Hou MM. et al, (2025), Nat Commun, 16

An experimental model of clinical immunity for human malaria

Hou MM. et al, (2025)

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Silk SE. et al, (2024), Lancet Infect Dis, 24, 1105 - 1117

Higher HIV-1 evolutionary rate is associated with cytotoxic T lymphocyte escape mutations in infants.

Nazziwa J. et al, (2024), J Virol, 98

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.

Mertens JE. et al, (2024), Vaccine, 42, 3621 - 3629

First Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5.1/Matrix-M ™ : a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants

Silk SE. et al, (2024)

Evaluation of Precision of the Plasmodium knowlesi Growth Inhibition Assay for Plasmodium vivax Duffy-Binding Protein-based Malaria Vaccine Development

Mertens JE. et al, (2024)

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial.

Martinez FJ. et al, (2024), NPJ Vaccines, 9

PvDBPII-Matrix M elicits polyfunctional antibodies that limit parasite growth in a challenge trial

Martinez FJ. et al, (2023)

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.

Hou MM. et al, (2023), Sci Transl Med, 15

Analyses of vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

Barrett JR. et al, (2023)

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens.

Barrett JR. et al, (2023), Front Immunol, 14

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum : safety and parasite growth dynamics

Salkeld J. et al, (2022)

Impact of a blood-stage vaccine on Plasmodium vivax malaria.

Hou MM. et al, (2022)

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics.

Salkeld J. et al, (2022), Front Immunol, 13

Load More